VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Berenson on Carfilzomib for Multiple Myeloma

James R. Berenson, MD
Published: Thursday, Nov 10, 2011

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research (IMBCR), Chief Executive Officer, Oncotherapeutics, discussed multiple myeloma at the Chemotherapy Foundation Symposium at the Marriott Marquis in New York City on November 9, 2011.

His presentation touched on the new drug carfilzomib; a proteasome inhibitor. The drug was examined in phase 1 and 2 trials looking at patients who had or had not received the proteasome inhibitor bortezomib (Velcade).

The carfilzomib trials demonstrated responses in refractory patients following progression with bortezomib. The trials demonstrated the highest recorded response in relapsed patients that had not previously received bortezomib.

The FDA is currently reviewing the application for carfilzomib and from his experience with the drug Berenson believes an approval will arrive in the spring of 2012.

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research (IMBCR), Chief Executive Officer, Oncotherapeutics, discussed multiple myeloma at the Chemotherapy Foundation Symposium at the Marriott Marquis in New York City on November 9, 2011.

His presentation touched on the new drug carfilzomib; a proteasome inhibitor. The drug was examined in phase 1 and 2 trials looking at patients who had or had not received the proteasome inhibitor bortezomib (Velcade).

The carfilzomib trials demonstrated responses in refractory patients following progression with bortezomib. The trials demonstrated the highest recorded response in relapsed patients that had not previously received bortezomib.

The FDA is currently reviewing the application for carfilzomib and from his experience with the drug Berenson believes an approval will arrive in the spring of 2012.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x